Xenon preconditioning: the role of prosurvival signaling, mitochondrial permeability transition and bioenergetics in rats

Anesthesia and Analgesia

Volumn 108, Issue 3, 2009, Pages 858-866

  Mio, Yasushi ^a,b   Shim, Yon Hee ^a   Richards, Ebony ^a   Bosnjak, Zeljko J ^a   Pagel, Paul S ^a   Bienengraeber, Martin ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GLYCOGEN SYNTHASE KINASE 3BETA; NITROGEN; OXYGEN; PROTEIN KINASE B; TRIPHENYLTETRAZOLIUM; WORTMANNIN; XENON; CARDIOTONIC AGENT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INHALATION ANESTHETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENERGY; CELL FUNCTION; CELL ISOLATION; CELL MEMBRANE DEPOLARIZATION; CELL RESPIRATION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXCISION; HEART; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART PROTECTION; HEMODYNAMICS; HYPOXIA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MEASUREMENT; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; MULTIPLE CYCLE TREATMENT; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REOXYGENATION; REPERFUSION; REPERFUSION INJURY; RISK; STAINING; WESTERN BLOTTING; WISTAR RAT; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; ENERGY METABOLISM; HEART INFARCTION PREVENTION; HEART MITOCHONDRION; HEART RATE; METABOLISM; PATHOLOGY; PERMEABILITY; PHOSPHORYLATION;

ANESTHETICS, INHALATION; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; CALCIUM; CARDIOTONIC AGENTS; ENERGY METABOLISM; GLYCOGEN SYNTHASE KINASE 3; HEART RATE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MITOCHONDRIA, HEART; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; OXYGEN CONSUMPTION; PERMEABILITY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; XENON;

EID: 61949171919     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e318192a520     Document Type: Article

References (39)

1. Kersten JR, Schmeling TJ, Pagel PS, Gross GJ, Warltier DC. Isoflurane mimics ischemic preconditioning via activation of KATP channels: reduction of myocardial infarct size with an acute memory phase. Anesthesiology 1997;87:361-70
2. Novalija E, Fujita S, Kampine JP, Stowe DF. Sevoflurane mimics ischemic preconditioning effects on coronary flow and nitric oxide release in isolated hearts. Anesthesiology 1999;91:701-12
3. Toller WG, Gross ER, Kersten JR, Pagel PS, Gross GJ, Warltier DC. Sarcolemmal and mitochondrial adenosine triphosphatedependent potassium channels: mechanism of desfluraneinduced cardioprotection. Anesthesiology 2000;92:1731-9
4. Weber NC, Toma O, Wolter JI, Obal D, Mullenheim J, Preckel B, Schlack W. The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC- and p38 MAPK. Br J Pharmacol 2005;144:123-32
5. Wilhelm S, Ma D, Maze M, Franks NP. Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology 2002;96:1485-91
6. Weber NC, Toma O, Damla H, Wolter JI, Schlack W, Preckel B. Upstream signaling of protein kinase C- in xenon-induced pharmacological preconditioning. Implication of mitochondrial adenosine triphosphate dependent potassium channels and phosphatidylinositol-dependent kinase-1. Eur J Pharmacol 2006;539:1-9
7. Weber NC, Toma O, Wolter JI, Wirthle NM, Schlack W, Preckel B. Mechanisms of xenon- and isoflurane-induced preconditioning - a potential link to the cytoskeleton via the MAPKAPK-2/HSP27 pathway. Br J Pharmacol 2005;146:445-55
8. Weber NC, Stursberg J, Wirthle NM, Toma O, Schlack W, Preckel B. Xenon preconditioning differently regulates p44/42 MAPK (ERK 1/2) and p46/54 MAPK (JNK 1/2 and 3) in vivo. Br J Anaesth 2006;97:298-306
9. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998;60:619-42
10. Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard JC, Zaugg M. Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3-. Anesthesiology 2005;103:987-95
11. Ljubkovic M, Mio Y, Marinovic J, Stadnicka A, Warltier DC, Bosnjak ZJ, Bienengraeber M. Isoflurane preconditioning uncouples mitochondria and protects against hypoxia-reoxygenation. Am J Physiol Cell Physiol 2007;292:C1583-C1590
12. Warltier DC, Zyvoloski MG, Gross GJ, Hardman HF, Brooks HL. Determination of experimental myocardial infarct size. J Pharmacol Methods 1981;6:199-210
13. Crompton M, Ellinger H, Costi A. Inhibition by cyclosporin A of a Ca2-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 1988;255: 357-60
14. Chiari PC, Bienengraeber MW, Pagel PS, Krolikowski JG, Kersten JR, Warltier DC. Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3- kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology 2005;102:102-9
15. Koblin DD, Fang Z, Eger EI 2nd, Laster MJ, Gong D, Ionescu P, Halsey MJ, Trudell JR. Minimum alveolar concentrations of noble gases, nitrogen, and sulfur hexafluoride in rats: helium and neon as nonimmobilizers (nonanesthetics). Anesth Analg 1998;87:419-24
16. Nakata Y, Goto T, Ishiguro Y, Terui K, Kawakami H, Santo M, Niimi Y, Morita S. Minimum alveolar concentration (MAC) of xenon with sevoflurane in humans. Anesthesiology 2001;94: 611-4
17. Xu Y, Tang P. Amphiphilic sites for general anesthetic action? Evidence from 129Xe-{1H} intermolecular nuclear overhauser effects. Biochim Biophys Acta 1997;1323:154-62
18. Preckel B, Ebel D, Mullenheim J, Frassdorf J, Thamer V, Schlack W. The direct myocardial effects of xenon in the dog heart in vivo. Anesth Analg 2002;94:545-51
19. Preckel B, Schlack W, Heibel T, Rutten H. Xenon produces minimal haemodynamic effects in rabbits with chronically compromised left ventricular function. Br J Anaesth 2002;88:264-9
20. Stowe DF, Rehmert GC, Kwok WM, Weigt HU, Georgieff M, Bosnjak ZJ. Xenon does not alter cardiac function or major cation currents in isolated guinea pig hearts or myocytes. Anesthesiology 2000;92:516-22
21. Griffiths EJ, Halestrap AP. Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 1993;25:1461-9
22. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307:93-8
23. Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003;549:513-24
24. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002;55:534-43
25. Piriou V, Chiari P, Gateau-Roesch O, Argaud L, Muntean D, Salles D, Loufouat J, Gueugniaud PY, Lehot JJ, Ovize M. Desfluraneinduced preconditioning alters calcium-induced mitochondrial permeability transition. Anesthesiology 2004;100:581-8
26. Pagel PS, Krolikowski JG, Shim YH, Venkatapuram S, Kersten JR, Weihrauch D, Warltier DC, Pratt PF Jr. Noble gases without anesthetic properties protect myocardium against infarction by activating prosurvival signaling kinases and inhibiting mitochondrial permeability transition in vivo. Anesth Analg 2007;105:562-9
27. Peart JN, Headrick JP. Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther 2007;114:208-21
28. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 2005;288: H971-H976
29. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7
30. Tong H, Chen W, Steenbergen C, Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 2000;87:309-15
31. Uchiyama T, Englelman RM, Maulik N, Das DK. Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation 2004;109:3042-9
32. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase kinase-3- mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004;113:1535-49
33. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-9
34. Preckel B, Weber NC, Sanders RD, Maze M, Schlack W. Molecular mechanisms transducing the anesthetic, analgesic, and organ-protective actions of xenon. Anesthesiology 2006;105: 187-97
35. Nagele P, Metz LB, Crowder CM. Xenon acts by inhibition of non-N-methyl-D-aspartate receptor-mediated glutamatergic neurotransmission in Caenorhabditis elegans. Anesthesiology 2005;103:508-13
36. Fryer RM, Patel HH, Hsu AK, Gross GJ. Stress-activated protein kinase phosphorylation during cardioprotection in the ischemic myocardium. Am J Physiol Heart Circ Physiol 2001;281:H1184-H1192
37. da Silva R, Lucchinetti E, Pasch T, Schaub MC, Zaugg M. Ischemic but not pharmacological preconditioning elicits a gene expression profile similar to unprotected myocardium. Physiol Genomics 2004;20:117-30
38. Otani H. Reactive oxygen species as mediators of signal transduction in ischemic preconditioning. Antioxid Redox Signal 2004;6:449-69
39. Maxwell MP, Hearse DJ, Yellon DM. Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res 1987;21:737-46